Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

• Published in: Nature reviews. Clinical oncology Vol. 16; no. 7; pp. 425 - 441
• Main Authors: Li, Xiaoyun, Wenes, Mathias, Romero, Pedro, Huang, Stanley Ching-Cheng, Fendt, Sarah-Maria, Ho, Ping-Chih
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.07.2019
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cell activation; Circuits; Clinical trials; Combined Modality Therapy; Drug delivery; Drug metabolism; Drug Repositioning; Drug Synergism; Fitness; Humans; Immune checkpoint; Immunosuppression; Immunosuppressive agents; Immunosurveillance; Immunotherapy; Immunotherapy - methods; Lymphocytes; Lymphocytes T; Metabolic Networks and Pathways - drug effects; Metabolic pathways; Metabolism; Mitochondria; Myeloid cells; Neoplasms - drug therapy; Neoplasms - immunology; Nutrient availability; Receptor mechanisms; Synergism; Tumor microenvironment; Tumor Microenvironment - drug effects; Tumors
• ISSN: 1759-4774; 1759-4782
• DOI: 10.1038/s41571-019-0203-7

The development of immunotherapies over the past decade has resulted in a paradigm shift in the treatment of cancer. However, the majority of patients do not benefit from immunotherapy, presumably owing to insufficient reprogramming of the immunosuppressive tumour microenvironment (TME) and thus limited reinvigoration of antitumour immunity. Various metabolic machineries and nutrient-sensing mechanisms orchestrate the behaviour of immune cells in response to nutrient availability in the TME. Notably, tumour-infiltrating immune cells typically experience metabolic stress as a result of the dysregulated metabolic activity of tumour cells, leading to impaired antitumour immune responses. Moreover, the immune checkpoints that are often exploited by tumour cells to evade immunosurveillance have emerging roles in modulating the metabolic and functional activity of T cells. Thus, repurposing of drugs targeting cancer metabolism might synergistically enhance immunotherapy via metabolic reprogramming of the TME. In addition, interventions targeting the metabolic circuits that impede antitumour immunity have been developed, with several clinical trials underway. Herein, we discuss how these metabolic circuits regulate antitumour immunity and the possible approaches to targeting these pathways in the context of anticancer immunotherapy. We also describe hypothetical combination treatments that could be used to better unleash the potential of adoptive cell therapies by enhancing T cell metabolism.